Johnson and Johnson recently announced FDA approval of their one-shot vaccine to the SARS-Cov-2 and has already begun shipping to vaccination centers across the country. Their published results have shown it to be highly effective in preventing severe disease and deaths (86%), although it has lower efficacy in preventing infections (72%) compared to the Pfizer and Moderna vaccines. Despite this latter comparison, experts have emphasized that the significant reduction in hospitalizations and deaths is the primary benefit of Johnson and Johnson vaccine, and should not deter anyone from choosing one vaccine over another.
Infectious disease specialists are particularly excited about this vaccine as unlike the other two previously approved vaccines, the Johnson and Johnson vaccine can be given as a single shot (versus two); can be stored in normal refrigerated temperatures for up to three months; and thus does not require special freezers or transportation in subzero temperatures as with the Pfizer and Moderna vaccines.
Furthermore, with the ability to transport under normal refrigeration, it is expected that the Johnson and Johnson vaccine can reach much more distant communities and clinics that might not otherwise be able to handle and store the earlier vaccines due to storage requirements. While current vaccine centers have focused on dense, urban areas, this gives a real boost towards widespread coverage with the ability to vaccinate more effectively in spread out,rural populations; as well as at-home delivery to elderly patients unable to travel.